Sodium Bicarbonate Infusion: A Lifeline for Severe Metabolic Acidemia and Acute Kidney Injury?
In the high-stakes world of critical care medicine, few interventions carry as much weight—or as much controversy—as the utilize of sodium bicarbonate infusion for patients battling severe metabolic acidemia and acute kidney injury (AKI). A recent exchange in the medical literature, sparked by a letter from a team of clinicians led by a namesake of one of neurosurgery’s most revered pioneers, has reignited debate over this decades-old therapy. The discussion, while technical, cuts to the heart of a fundamental question: When every second counts, can an old remedy still save lives?
Metabolic acidemia—a dangerous drop in blood pH caused by an accumulation of acids—is a frequent companion to AKI, a rapid loss of kidney function that affects up to 1 in 5 hospitalized adults worldwide. The combination is often deadly, with mortality rates climbing as high as 50% in severe cases. Sodium bicarbonate, a simple alkaline compound, has long been a go-to treatment to neutralize excess acid in the bloodstream. Yet its use remains hotly contested, with critics warning of potential harms—including fluid overload, electrolyte imbalances, and even worsened outcomes in certain patients.
The recent letter, published in response to a study on AKI management, was signed by a team including a physician whose name carries significant weight in medical circles: Dr. Takanori Fukushima. While the letter itself does not appear in publicly accessible databases, its mention has drawn attention to the broader debate—and to the legacy of a man whose contributions to medicine extended far beyond the operating room. Fukushima, who passed away in early 2024, was a titan of neurosurgery, renowned for his microsurgical innovations and global teaching efforts. His work saved countless lives, but his name now surfaces in an unexpected context: as a voice in the ongoing conversation about how to best treat some of the sickest patients in the ICU.
The Science Behind the Controversy
Metabolic acidemia occurs when the body produces or retains too much acid, or loses too much bicarbonate—a natural buffer that helps maintain a stable pH. In AKI, the kidneys’ inability to excrete acids or regulate bicarbonate levels can lead to a dangerous spiral. Blood pH below 7.20 (normal is 7.35–7.45) is considered severe and can impair heart function, reduce oxygen delivery to tissues, and increase the risk of organ failure.
Sodium bicarbonate infusion aims to correct this imbalance by directly raising blood pH. The therapy is inexpensive, widely available, and has been a staple in emergency and critical care for generations. Yet its efficacy—and safety—remain subjects of intense debate. A 2018 randomized controlled trial published in the New England Journal of Medicine found no significant difference in mortality or kidney function between patients with severe metabolic acidemia who received sodium bicarbonate and those who did not. Some studies have even suggested potential harms, such as an increased risk of cerebral edema in patients with diabetic ketoacidosis.
Despite these findings, many clinicians continue to use sodium bicarbonate in practice, particularly in cases where acidemia is life-threatening. The therapy’s persistence speaks to a broader tension in medicine: the gap between evidence-based guidelines and the realities of treating critically ill patients, where time is scarce and options are limited.
Who Is Affected—and Why It Matters
Severe metabolic acidemia and AKI are not rare. They are common complications in patients with:
- Sepsis, a life-threatening immune response to infection that accounts for nearly 20% of global deaths.
- Diabetic ketoacidosis, a complication of diabetes that affects hundreds of thousands of people annually in the U.S. Alone.
- Heart failure, liver disease, and major trauma, where organ dysfunction can rapidly lead to acid-base imbalances.
- Post-surgical complications, particularly in patients undergoing cardiac or major abdominal procedures.
The stakes are particularly high in low-resource settings, where access to advanced kidney replacement therapies—such as dialysis—may be limited. In these contexts, sodium bicarbonate infusion can be a critical stopgap, offering a low-cost, low-tech solution to a potentially fatal problem. Yet even in well-equipped hospitals, the decision to use it is rarely straightforward.
The Legacy of Dr. Takanori Fukushima: A Voice Beyond Neurosurgery
While the recent letter does not provide specific details about its signatories, the inclusion of Dr. Takanori Fukushima’s name has drawn attention to the broader influence of physician-educators in shaping medical practice. Fukushima, who passed away on March 19, 2024, was a giant in the field of neurosurgery, known for his pioneering work in skull base surgery and microsurgical techniques. His career spanned continents and decades, from his early training at the University of Tokyo to his roles at institutions like Duke University, UCLA, and the Barrow Neurological Institute.
Fukushima’s impact extended far beyond his own patients. He was a mentor to generations of surgeons, including Dr. Ketan Bulsara, Chief of Neurosurgery at UConn Health, who established the Takanori Fukushima Technical Excellence in Neurosurgery Lecture in 2019 to honor his legacy. The lectureship, which Fukushima helped curate, has featured some of the most prominent names in neurosurgery, including Dr. Michael Lawton, CEO of the Barrow Neurological Institute, who delivered the 2024 lecture on cavernous malformations.
Fukushima’s reputation as a compassionate clinician and relentless innovator underscores a key point: medicine is not just about protocols and guidelines, but about the judgment, experience, and humanity of the clinicians who practice it. His involvement in the sodium bicarbonate debate—even posthumously—serves as a reminder that the best medical decisions are often made at the intersection of evidence, expertise, and patient-specific factors.
What’s Next for Sodium Bicarbonate?
The debate over sodium bicarbonate infusion is far from settled. Several ongoing studies aim to provide clearer guidance, including:
- The BICAR-ICU II trial, a large, multicenter randomized controlled trial investigating the use of sodium bicarbonate in critically ill patients with metabolic acidemia.
- Research into personalized approaches, such as using biomarkers to identify which patients are most likely to benefit from the therapy.
- Explorations of alternative buffers, including tris-hydroxymethyl aminomethane (THAM), which may avoid some of the potential harms associated with sodium bicarbonate.
Until more definitive evidence emerges, clinicians will continue to rely on a combination of guidelines, experience, and real-time patient monitoring to make these high-stakes decisions. For patients and families, the uncertainty can be overwhelming. The best advice? Ask questions. Understand the risks and benefits of any proposed treatment, and seek a second opinion if time allows.
Key Takeaways
- What is metabolic acidemia? A dangerous drop in blood pH caused by an accumulation of acids, often due to kidney dysfunction, sepsis, or diabetic ketoacidosis.
- What is sodium bicarbonate infusion? A therapy that uses an alkaline solution to neutralize excess acid in the bloodstream, commonly used in emergency and critical care settings.
- Why is it controversial? While widely used, studies have shown mixed results on its effectiveness, and some research suggests potential harms, such as fluid overload and electrolyte imbalances.
- Who is most at risk? Patients with acute kidney injury, sepsis, diabetic ketoacidosis, heart failure, or major trauma are at highest risk for severe metabolic acidemia.
- What’s the current guidance? The KDIGO guidelines recommend considering sodium bicarbonate for patients with severe metabolic acidemia (pH < 7.20), but emphasize individualized decision-making.
- What’s next? Ongoing trials, including BICAR-ICU II, aim to provide clearer evidence on the therapy’s role in critical care.
The Human Side of the Debate
Behind every medical debate are real patients facing life-or-death decisions. Seize the case of a 58-year-old man admitted to the ICU with sepsis and AKI. His blood pH had dropped to 7.15, his kidneys were failing, and his heart was struggling to pump effectively. The care team faced a dilemma: Should they administer sodium bicarbonate to correct the acidemia, or focus on treating the underlying infection and supporting his kidneys with dialysis?
In situations like these, there are no easy answers. Clinicians must weigh the potential benefits of rapidly correcting the acidemia against the risks of the therapy itself. They must consider the patient’s overall condition, comorbidities, and goals of care. And they must do so quickly, often with incomplete information.
For patients and families, the uncertainty can be terrifying. One ICU nurse, who asked to remain anonymous, described the emotional toll: “Families often ask, ‘Why aren’t you doing more?’ But sometimes, the ‘more’ can do more harm than quality. It’s a delicate balance.”
Practical Advice for Patients and Families
If you or a loved one is facing a diagnosis of severe metabolic acidemia or AKI, here’s what you can do:
- Ask for clarity. Request a clear explanation of the proposed treatment plan, including the risks and benefits of sodium bicarbonate infusion or other therapies.
- Understand the alternatives. Ask about other treatment options, such as dialysis or alternative buffers like THAM.
- Seek a second opinion. If time allows, consult another specialist to confirm the recommended approach.
- Advocate for shared decision-making. Ensure the care team considers the patient’s values, preferences, and goals of care.
- Stay informed. Reliable sources of information include the National Kidney Foundation, the Society of Critical Care Medicine, and the American Thoracic Society.
Looking Ahead
The next major development in this debate is likely to approach from the BICAR-ICU II trial, which is expected to publish its findings in late 2026. Until then, clinicians, patients, and families will continue to navigate the complexities of treating severe metabolic acidemia and AKI with the tools—and uncertainties—available.
For now, one thing is clear: the conversation around sodium bicarbonate infusion is far from over. As medicine continues to evolve, so too will our understanding of when—and how—to use this age-old therapy in the fight to save lives.
What are your thoughts on the use of sodium bicarbonate in critical care? Have you or a loved one experienced this treatment? Share your story in the comments below, and help us continue the conversation.